Prevention by methylprednisolone of increased circulating tumor necrosis factor-α levels and lung injury associated with systemic inflammatory response syndrome due to intraperitoneal hyperthermia

Anesthesia and Analgesia

Volumn 88, Issue 4, 1999, Pages 771-776

  Sumida, Megumi ^a   Inaba, Hideo ^b   Isawa, Eiji ^d   Fujimoto, Shigeru ^d   Satoh, Toshihiko ^c   Kawamata, Miwako ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Dept of Surgery   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INFLAMMATION; LUNG FUNCTION; LUNG INJURY; MALE; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0032922654     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199904000-00017     Document Type: Article

References (25)

1. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987;316:379-85.
2. Sherry B, Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol 1988;107:1269-77.
3. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/ tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170: 1627-33.
4. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 1995;4:389-96.
5. Sumida M, Isawa E, Kobayashi K, et al. TNF-α and endotoxin serum levels in cancer patients undergoing intraperitoneal hyperthermic perfusion. Int J Hyperthermia 1996;12:607-15.
6. Miche HR, Spriggs DR, Manogue KR, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988;104:280-6.
7. Blic M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-9.
8. Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema: comparison to septic acute lung injury. Am Rev Respir Dis 1988;137:1364-70.
9. Pinsky MR, Vincent J-L, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
10. Evans DA, Jacobs DO, Revhaug A, Wilmore DW. The effects of tumor necrosis factor and their selective inhibition by ibuprofen. Ann Surg 1988;209:312-21.
11. Waage A, Bakke O. Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988;63:299-302.
12. Zuckerman SH, Shellhaas J, Butler LD. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 1989;19:301-5.
13. Beutler B, Krochin N, Milsark IW, et al. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232:977-80.
14. Marks JD, Marks CB, Luce JM, et al. Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990; 141:94-7.
15. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
16. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234: 470-4.
17. Brigham KL, Bowers RE, Mckeen CR. Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. J Clin Invest 1981;67:1103-10.
18. Sheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283-6.
19. Ridtimski A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation - MPS potently down-regulates cytokine-induced COX-2 mRNA expression. Biochem J 1996;318:325-31.
20. Doherty GM, Jensen JC, Bresh CM, Norton JA. Hormonal regulation of inflammatory cell cytokine transcript and bioactivity production in response to endotoxin. Cytokine 1992;4:55-62.
21. Kuei JH, Tashkin DP, Figlin RA. Pulmonary toxicity of recombinant human tumor necrosis factor. Chest 1989;96:334-8.
22. Stephens KE, Ishizaka A, Wu ZH, et al. Granulocyte depletion prevents tumor necrosis factor-mediated acute lung injury in guinea pigs. Am Rev Respir Dis 1988;138:1300-7.
23. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
24. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
25. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65.